Search the Newsreel

Retirement Systems of Alabama Sells 4,152 Shares of Medpace Holdings, Inc. $MEDP

Retirement Systems of Alabama reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.6% in the second quarter, selling 4,152 shares but still retaining 59,199 shares valued at approximately $31.4 million. Despite this sale, other institutional investors increased their positions, and Medpace reported strong …

Medpace (MEDP) Stock May Sit Below Fair Value While Earnings Look Rich

Atria Investments Inc Has $1.01 Million Position in Medpace Holdings, Inc. $MEDP

Atria Investments Inc significantly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 66.2% in the second quarter, now holding 1,907 shares valued at approximately $1.01 million. Despite insider sales totaling $30.88 million, Medpace reported strong quarterly earnings of $4.25 per share, exceeding estimates, …

Medpace Holdings (MEDP) director McCarthy sells 1,140 shares at $605.37

Medpace Holdings, Inc. director Cornelius P. McCarthy III sold 1,140 shares of common stock on August 11, 2026, at a price of $605.37 per share, totaling approximately $690,000. This transaction was an open market sale and was not conducted under a Rule 10b5-1 trading …

Medpace Holdings Insider Sold Shares Worth $690,122, According to a Recent SEC Filing

An insider at Medpace Holdings sold shares valued at $690,122, as disclosed in a recent SEC filing. This transaction follows another insider sale of $4.5 million in shares reported on July 29th. Medpace Holdings, a clinical contract research organization, has seen recent analyst price …

Medpace Holdings (MEDP) CEO sells 23,144 shares, reports 4.73M held via LLC

Medpace Holdings, Inc. President & CEO August J. Troendle sold a total of 23,144 shares of Medpace common stock on August 10 and 11, 2026, for approximately $13.98 million. The sales were executed through limit orders during an open window period. Troendle also reported …

Here's How Much a $1000 Investment in Medpace Made 10 Years Ago Would Be Worth Today

This article analyzes the hypothetical return on a $1000 investment in Medpace (MEDP) made ten years ago, calculating its current value to be $21,788.41, representing a 2,078.84% gain. It also provides an in-depth look at Medpace's business operations, financial performance, and future outlook, noting …

Medpace Holdings, Inc. $MEDP is Wasatch Advisors LP's 5th Largest Position

Wasatch Advisors LP has reduced its stake in Medpace Holdings, Inc. (MEDP) by 17.7%, but it still remains their fifth-largest holding, representing 2.2% of their portfolio. Despite the firm's strong quarterly earnings, analysts maintain a cautious "Hold" rating with an average price target below …

Medpace director McCarthy sells $465,131 in company shares

Medpace Holdings director Cornelius P. McCarthy III sold 795 shares of company stock for $465,131 after exercising options to acquire 3,858 shares. Following these transactions, McCarthy directly holds 13,415 shares. The sale comes as Medpace reported strong Q2 2026 financial results, exceeding Wall Street …

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Medpace Holdings, Inc. (MEDP) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by Medpace Holdings, Inc. (NASDAQ:MEDP) and certain of its officers and/or directors. The firm is encouraging shareholders who purchased Medpace securities prior to April 22, 2025, and still hold them, to …

Medpace (MEDP) director exercises 3,858 options and sells 795 common shares

Medpace Holdings, Inc. director Cornelius P. McCarthy III exercised options for 3,858 shares of common stock at $84.36 per share on August 7, 2026, and subsequently sold 795 of these shares at $585.071 per share. The exercised option had vested in 2021 and was …

Assenagon Asset Management S.A. Sells 90,551 Shares of Medpace Holdings, Inc. $MEDP

Assenagon Asset Management S.A. significantly reduced its stake in Medpace Holdings, Inc. by selling 90,551 shares, leaving it with 25,772 shares valued at $13.65 million. Despite this, Medpace exceeded Q2 earnings expectations with $4.25 EPS and $707.33 million in revenue, and issued strong fiscal …

CON or MEDP: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own …

Medpace Holdings faces lawsuit over alleged misleading growth info causing inflated stock prices.

Medpace Holdings Inc. is being investigated by Kuehn Law for allegedly misleading shareholders with misrepresented business metrics, including backlog cancellations and growth projections. The lawsuit claims these overly optimistic expectations led investors to purchase stock at inflated prices. Shareholders who bought stock before April …

Kuehn Law Encourages Investors of Medpace Holdings, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating Medpace Holdings, Inc. (NASDAQ: MEDP) for potential breaches of fiduciary duties by its officers and directors. A federal securities lawsuit alleges that Medpace misrepresented its backlog cancellation rates, business conditions, and ability to maintain its projected 1.15 book-to-bill ratio, …

Should Medpace’s (MEDP) Golden Cross and Upgraded Estimates Prompt a Fresh Look at Its Valuation?

Medpace Holdings (MEDP) recently experienced a "golden cross" and upward revisions to earnings estimates, indicating technical momentum and improved financial expectations. The article examines how these factors interact with the company's investment narrative, focusing on its ability to convert backlog into revenue while managing …

Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Medpace securities before April 22, 2025, and still hold them, to contact them …

Medpace Holdings, Inc. SEC Filing (Aug 7, 2026)

This article reports on Medpace Holdings, Inc.'s SEC Form 144 filing on August 7, 2026, detailing a proposed sale of securities. The filing indicates the sale of 795 shares of common stock acquired through stock option exercise on the same date, with an aggregate …

Should You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$585?

The article discusses whether Medpace Holdings, Inc. (NASDAQ:MEDP) is a good investment at its current share price of US$585. It delves into the company's valuation, considering factors such as its price-to-earnings (P/E) ratio and future growth prospects. The analysis aims to help potential investors …

Medpace Holdings Inc (MEDP) Stock News Today

This page provides news and analysis for Medpace Holdings Inc (MEDP). It highlights the company's stock performance, including a recent surge after strong earnings, and offers various financial and analytical tools for investors. The article mentions a significant event where Medpace's strong earnings caused …

Medpace (MEDP) Just Flashed Golden Cross Signal: Do You Buy?

Medpace Holdings, Inc. (MEDP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MEDP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross." Considered an important …

Medpace Holdings (MEDP) Updates 2026 Guidance, Is The Upside Already Priced In?

Medpace Holdings, Inc. $MEDP Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in Medpace Holdings, Inc. ($MEDP) by 12.5% in the first quarter, selling 2,063 shares. Despite this, Medpace reported strong quarterly results with higher-than-expected EPS and revenue, and issued positive fiscal 2026 EPS guidance. The stock opened …

Is MEDP Worth Buying as Growth Collides With a Premium Valuation?

Medpace Holdings, Inc. (MEDP) exhibits compelling growth with double-digit earnings, strong profitability, and improving bookings, along with a significant pipeline for 2027. However, its valuation is considerably higher than industry and market averages. While the company's operational quality is high, the premium valuation and …

Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (NASDAQ:MEDP) securities. The investigation concerns whether Medpace and its officers/directors engaged in corporate wrongdoing, particularly for investors who purchased shares before April 22, 2025, and still hold …

Can MEDP's Record Q2 Bookings Build a Stronger Growth Path for 2027?

Medpace Holdings, Inc. MEDP regained commercial momentum in the second quarter of 2026 as record awards and a higher book-to-bill ratio reversed the weaker first-quarter trend. The central issue is timing. Better demand can strengthen backlog and support future growth, but study starts, pre-backlog …

Pacer Advisors Inc. Sells 107,271 Shares of Medpace Holdings, Inc. $MEDP

Pacer Advisors Inc. significantly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the first quarter of 2026, selling 107,271 shares and retaining 46,381 shares valued at approximately $22.3 million. Despite this reduction, other institutional investors have increased their holdings, and the company reported …

Amundi Buys 57,288 Shares of Medpace Holdings, Inc. $MEDP

Amundi increased its stake in Medpace Holdings, Inc. (MEDP) by 1,487.6% in the first quarter, acquiring 57,288 additional shares and bringing its total holdings to 61,139 shares valued at $29.4 million. Despite institutional ownership of 77.98% and strong quarterly earnings, analysts maintain a "Hold" …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (NASDAQ:MEDP) who bought securities prior to April 22, 2025, and still hold them. The investigation aims to determine if Medpace and its officers engaged in corporate wrongdoing. …

Have Medpace Holdings Insiders Been Selling Stock?

Recent insider transactions at Medpace Holdings, Inc. revealed that an insider sold US$4.5 million worth of shares, reducing their holding by 11%. Over the last year, the CEO also sold US$62 million worth of shares at a price close to the current share price. …

Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Medpace Holdings, Inc. (NASDAQ: MEDP) investors who purchased securities before April 22, 2025, concerning alleged corporate wrongdoing by the company's officers and/or directors. The firm encourages affected stockholders to contact them for …

Medpace Holdings President & CEO Trades $4.35M In Company Stock

Medpace Holdings's President & CEO, August J Troendle, sold 7,238 shares of company stock worth $4.35 million on July 29, 2026, according to an SEC filing. Despite this insider sale, the company reported strong revenue growth of 17.24% for the quarter ending June 30, …

Medpace Holdings (MEDP) Is Up 10.8% After Boosting 2026 Outlook And Retiring 17% Of Shares - Has The Bull Case Changed?

Medpace Holdings (MEDP) saw a 10.8% stock increase after reporting strong Q2 2026 results, boosting its 2026 outlook, and completing a significant share repurchase program that retired 17.25% of its shares. The company now projects 2026 revenue between US$2.81 billion and US$2.89 billion, with …